内部人交易雷达

美国 · SEC Form 4 · 快照日期： 2026-10-18 · 构建时间： 2026-10-18 · English

← 美国市场 · 覆盖记录

美国 · SEC FORM 4

Xenon Pharmaceuticals Inc.

XENE · Nasdaq · CIK 0001582313 · Healthcare · Biotechnology

内部人信号

51.5 / 100

2 位买方 · 2 条买入交易行 · $1.7M 买入总额

为什么有这个信号？

买方广度较低
买入规模中等
角色中等
近期性中等
确信度较低
评分构成

每条进度条表示其对当前分数的贡献；权重和公式保持不变。

Cluster+14.0 / 35
买入规模+14.2 / 25
角色+13.0 / 20
近期性+7.4 / 10
确信度+2.9 / 10

哪些因素限制了当前分数？

  • ⚠ Cluster breadth is moderate · 2 insider(s), not 4+
  • ⚠ 角色得分低 · 买入者中职位最高的是：PRESIDENT & CEO（CEO、董事长和持股 10% 以上的股东得分最低）
  • ⚠ Buying conviction is reduced by concurrent selling
  • ✓ Recent activity · latest purchase 2026-09-30

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后，不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。

内部人活动时间轴

申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。

AprMayJunJulAugSepOct
GANNON STEVENDirector
○○○▼
Svoronos DawnDirector
○○○
PATOU GARYDirector
○▼
Cannon GillianDirector
○▼
Kelly Thomas PatrickChief Financial Officer
●○
Machado PatrickDirector
○
● 买入▼ 卖出○ 其他

Showing the six most active owners; 4 additional owner(s) remain in Form 4 申报证据.

买方广度与集中度

合资格买方2
买入集中度67%最大买方： MORTIMER IAN · $1.1M
聚集买入 · 15天2 insiders峰值活动： 2026-09-30–2026-09-30

Roles in the peak window: Chief Financial Officer, PRESIDENT & CEO. Concentration uses priced qualifying P lines only and does not change the saved score.

信号历史

51.5 / 100

最新留档分数

↓ -0.3 pts相对上一个留档快照
  1. 52.4
  2. 52.2
  3. 52.0
  4. 51.8
  5. 51.5

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

近期 Form 4 活动

2买入
26卖出
23其他 Form 4 交易行
25SEC 申报 · 365天
买入2 qualifying P line(s) · 180 days
卖出5 sale line(s) · 仅供背景
其他12 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not detected in parsed evidence

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

市场背景

市场背景补充近期价格表现与风险信息，不影响内部人信号。

价格表现

1M
-38.0%
3M
-46.2%
6M
-37.6%
12M
-7.2%

波动率与流动性

波动率
57.1%
Beta
—
平均每日成交额
USD 51.6M

估值

市值
—
P/E
—

基本面

利润率
—
ROE
-59.5%
细分行业
Biotechnology

市场数据

价格数据截至：2026-10-11 · 价格来源：OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件：ROE · 财年截止日：2025-12-31 · Status: PASS

空头余额

空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。

空头股数
6,041,487
上期报告
6,444,815
日均成交量
3,834,835
回补天数
1.6

FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。

历史股票买入

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting owner类型证券股数平均价格估算金额来源
2026-09-30MORTIMER IAN买入 (P)Common Shares30,000USD 37.38USD 1,121,400SEC 申报 ↗
2026-09-30Kelly Thomas Patrick买入 (P)Common Shares15,000USD 37.32USD 559,740SEC 申报 ↗
2022-01-21KENNEY CHRISTOPHER JOHN买入 (P)Common Shares700USD 28.81USD 20,167SEC 申报 ↗
2021-12-06Von Seggern Christopher买入 (P)Common Shares4,000USD 24.40USD 97,600SEC 申报 ↗

Form 4 申报证据

51 transaction lines in the latest 365-day window; 241 in local history.

日期申报人类型证券股数平均价格估算金额来源
2026-10-15Kelly Thomas Patrick期权行权／转换 (M)Common Shares7,500USD —USD —SEC 申报 ↗
2026-09-30MORTIMER IAN买入 (P)Common Shares30,000USD 37.38USD 1,121,400SEC 申报 ↗
2026-09-30Kelly Thomas Patrick买入 (P)Common Shares15,000USD 37.32USD 559,740SEC 申报 ↗
展开近期 Form 4 证据 (30 grouped rows)
日期申报人类型证券股数平均价格估算金额来源
2026-10-15Kelly Thomas Patrick期权行权／转换 (M)Common Shares7,500USD —USD —SEC 申报 ↗
2026-09-30MORTIMER IAN买入 (P)Common Shares30,000USD 37.38USD 1,121,400SEC 申报 ↗
2026-09-30Kelly Thomas Patrick买入 (P)Common Shares15,000USD 37.32USD 559,740SEC 申报 ↗
2026-09-01Svoronos Dawn期权行权／转换 (M)Common Shares5,144USD 8.15USD 41,924SEC 申报 ↗
2026-08-28KENNEY CHRISTOPHER JOHN卖出 (S)Common Shares7,068USD 60.25USD 425,849SEC 申报 ↗
2026-08-11GANNON STEVEN卖出 (S)Common Shares10,000USD 64.06USD 640,600SEC 申报 ↗
2026-06-05PATOU GARY卖出 (S)Common Shares1,322USD 53.14USD 70,251SEC 申报 ↗
2026-06-05Cannon Gillian卖出 (S)Common Shares1,190USD 53.14USD 63,237SEC 申报 ↗
2026-06-01Svoronos Dawn期权行权／转换 (M)Common Shares2,645USD —USD —SEC 申报 ↗
2026-06-01Svoronos Dawn代扣税 (F)Common Shares1,416USD 53.41USD 75,629SEC 申报 ↗
2026-06-01PATOU GARY期权行权／转换 (M)Common Shares2,645USD —USD —SEC 申报 ↗
2026-06-01Machado Patrick期权行权／转换 (M)Common Shares2,645USD —USD —SEC 申报 ↗
2026-06-01Gover Justin D.期权行权／转换 (M)Common Shares2,645USD —USD —SEC 申报 ↗
2026-06-01GAROFALO ELIZABETH A.期权行权／转换 (M)Common Shares2,645USD —USD —SEC 申报 ↗
2026-06-01GANNON STEVEN期权行权／转换 (M)Common Shares2,645USD —USD —SEC 申报 ↗
2026-06-01GANNON STEVEN代扣税 (F)Common Shares1,416USD 53.41USD 75,629SEC 申报 ↗
2026-06-01Cannon Gillian期权行权／转换 (M)Common Shares2,645USD —USD —SEC 申报 ↗
2026-05-12GANNON STEVEN期权行权／转换 (M)Common Shares3,500USD 7.38USD 25,830SEC 申报 ↗
2026-03-13MORTIMER IAN卖出 (S)Common Shares7,308USD 55.23USD 403,621SEC 申报 ↗
2026-03-13KENNEY CHRISTOPHER JOHN卖出 (S)Common Shares1,410USD 55.23USD 77,874SEC 申报 ↗
2026-03-13DiFabio Andrea卖出 (S)Common Shares1,342USD 55.23USD 74,119SEC 申报 ↗
2026-03-12MORTIMER IAN期权行权／转换 (M)Common Shares12,500USD —USD —SEC 申报 ↗
2026-03-12KENNEY CHRISTOPHER JOHN期权行权／转换 (M)Common Shares3,750USD —USD —SEC 申报 ↗
2026-03-12DiFabio Andrea期权行权／转换 (M)Common Shares3,750USD —USD —SEC 申报 ↗
2026-03-10MORTIMER IAN卖出 (S)Common Shares11,269USD 60.11USD 677,380SEC 申报 ↗
2026-03-10KENNEY CHRISTOPHER JOHN卖出 (S)Common Shares2,771USD 60.11USD 166,565SEC 申报 ↗
2026-03-10DiFabio Andrea卖出 (S)Common Shares2,607USD 60.11USD 156,707SEC 申报 ↗
2026-03-09MORTIMER IAN卖出 (S)Common Shares270,000USD 60.33USD 16,289,142SEC 申报 ↗
2026-03-09MORTIMER IAN期权行权／转换 (M)Common Shares290,000USD —USD —SEC 申报 ↗
2026-03-09KENNEY CHRISTOPHER JOHN期权行权／转换 (M)Common Shares7,500USD —USD —SEC 申报 ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

快照与身份

快照日期2026-10-18
排名版本US-v1.2
数据质量PASS ELIGIBLE · —
股票代码XENE
CIK0001582313
行业Healthcare
细分行业Biotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
交易所Nasdaq

数据覆盖

本地 Form 4 历史241 transaction lines from 2020-05-26 to 2026-10-15
4 P purchase lines · 106 S sale lines · 131 other lines
SEC 公司申报打开 SEC 申报 ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.